Chan Lik Yuen
 Assistant Dean, External Affairs - Assistant De
Medicine and Therapeutics
The Chinese University of Hong Kong
Hong Kong
Biography
Dr. CHAN Lik Yuen is affiliated to Medicine and Therapeutics, CUHK . Dr. CHAN Lik Yuen is currently providing services as Assistant Dean, External Affairs - Assistant Dean.Professor. Dr. CHAN Lik Yuen has authored and co-authored multiple peer-reviewed scientific papers and presented works at many national and International conferences. Dr. CHAN Lik Yuen contributions have acclaimed recognition from honourable subject experts around the world. Dr. CHAN Lik Yuen is actively associated with different societies and academies. Dr. CHAN Lik Yuen academic career is decorated with several reputed awards and funding. Dr. CHAN Lik Yuen research interests include Viral hepatitis, liver fibrosis, liver cancer, anti-viral therapy, fatty liver disease.He specialises in Gastroenterology and Hepatology
Research Interest
Viral hepatitis, liver fibrosis, liver cancer, anti-viral therapy, fatty liver disease
Publications
-
P Marcellin, SH Ahn, X Ma, FA Caruntu, WY Tak, M Elkashab, WL Chuang, SG Lim, F Tabak, R Mehta, J Petersen, GR Foster, L Lou, EB Martins, P Dinh, A Corsa, P Charuworn, GM Subramanian, H Reiser, HW Reesink, S Fung, SI Strasser, H Trinh, M Buti, GB Gaeta, AJ Hui, G Papatheodoridis, R Flisiak, HLY Chan, on behalf of the study 149 investigators. Combination of tenofovir disoproxil fumarate and peginterferon alfa-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology 2016;150:134-44.
-
VWS Wong, GLH Wong, JCL Yeung, CYK Fung, JKL Chan, ZHY Chang, CTY Kwan, HW Lam, J Limquiaco, AML Chim, HLY Chan. Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: a prospective cohort study. Hepatology 2016;63:754-63.
-
HLY Chan, SH Ahn, TT Chang, CY Peng, D Wong, CS Coffin, SG Lim, PJ Chen, HLA Janssen, P Marcellin, L Serfaty, S Zeuzem, D Cohen, L Critelli, D Xu, M Wind-Rotolo, E Cooney, and the LIRA-B study team. Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis: a randomized phase 2b study (LIRA-B). J Hepatol 2016;64:1011-9.
